Research Article

Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma

Table 2

Univariate and multivariate analysis for variables associated with survival.

VariableUnivariate analysisMultivariate analysis
HR95% CI valueHR95% CI value

Age (years)
 ≥71971.660.67–4.090.27
 ≤7074
Gender
 M1183.430.79–14.860.08
 F53
Etiology
 NBNC306.262.54–15.45<0.014.321.46–12.8<0.01
 B/C141
Child-Pugh
 B, C302.020.82–4.980.13
 A141
Platelet (/mL)
 ≤12.0 × 1041040.810.32–2.020.65
 ≥12.1 × 10467
ALT (IU/L)
 ≥40651.080.43–2.700.87
 ≤39106
AFP (ng/mL)
 ≥20.1741.660.67–4.100.27
 ≤20.097
DCP (mAU/mL)
 ≥40603.081.23–7.690.021.140.39–3.320.82
 ≤39106
AFP-L3 (%)
 ≥10.0342.851.12–7.270.031.800.62–5.220.28
 ≤9.9137
HCC stage (TNM)
 III, IV453.941.58–9.81<0.011.480.50–4.310.48
 I, II136
Semiannual surveillance
 No736.841.98–23.64<0.014.551.21–17.080.02
 Yes98
Curative therapy
 No568.712.88–26.33<0.015.931.88–18.67<0.01
 Yes115

Curative therapy includes operative resection and radiofrequency ablation.